REGENXBIO and Voyager Therapeutics Announce Exercise of Options for Rights to NAV Vectors
ROCKVILLE, Md. and CAMBRIDGE, Mass., Nov. 29, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based …